May had failed to win a parliamentary majority on Britain's withdrawal from the European Union.Europe Politicsread more
Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
President Donald Trump on Thursday directed the U.S. intelligence community to "quickly and fully cooperate" with Attorney General William Barr's investigation into the...Politicsread more
Despite a decline in global commercial real estate markets, Asia-Pacific continues to enjoy a record-breaking growth — thanks to China, according to the Global Capital Flows...Real Estateread more
The Wall Street Journal and The New York Times, citing people familiar with the deal, reported that $30 million would go to plaintiffs and $14 million would be used to pay...Entertainmentread more
Danish shipping group A.P. Moller-Maersk on Friday posted first-quarter profit close to expectations and warned that trade tensions and slowing economic growth constitute...Earningsread more
Wall Street is becoming convinced that both the White House and Beijing are willing to engage in a protracted trade war that could begin to hit consumers and slow global...Market Insiderread more
The U.S. Commerce Department said its proposed rule would amend the normal countervailing duty process to include new criteria for currency undervaluation.World Economyread more
SpaceX sent 60 satellites into space in a key first mission toward the company's own high-speed internet network.Internetread more
Zilingo founder Ankiti Bose says working as an investment analyst helped her build her near-$1 billion fashion start-up.Ditching the Corporate Liferead more
TransferWise, the money transfer start-up, was valued at $3.5 billion after investors bought $292 million of shares in a secondary sale.Technologyread more
Johnson & Johnson Chairman and CEO Alex Gorsky told CNBC on Wednesday he expects the company's pharmaceutical business will be able to successfully navigate any changes in health care as a result of President Donald Trump's new plan aimed a reducing drug prices.
At the same time, Gorsky warned the Trump administration to be careful not to impose "unintended consequences" on the U.S. health-care system, which is incredibly complex. He did not elaborate.
"We know there are going to be changes in the pricing system. That's why we have to continually innovate," Gorsky said in a "Squawk Box " interview with CNBC's Meg Tirrell. He added that J&J, whose pharma unit accounted for 47 percent of 2017 net sales, is still analyzing Trump's plan, which was unveiled on Friday.
Trump's plan, among other changes, will consider an alternative system for buying Medicare Part B drugs, including many cancer treatments and infused biotech drugs.
J&J's top-selling arthritis drug Remicade, which is covered under Part B, could be affected by Trump's plan. Gorsky said the company has looked at its entire portfolio and it's reinventing it. He said two other drugs — Simponi and Stelara, designed to treat autoimmune diseases — have actually exceeded sales of Remicade.
Earlier Wednesday, J&J announced it would relaunch its baby-care products, which saw a 20 percent sales decline since 2011 to $1.9 billion.
Speaking just hours before the company's every-other-year consumer products and medical devices analyst meeting, Gorsky said J&J is trying to be more like a "start-up" with its baby brand, focusing on the changing needs of "millennial moms," who favor baby products with more natural ingredients.
"We realize that over the past few years that we probably got a little bit behind the curve," he said. "But what you're going to hear about today is that we totally reformulated the brand where we're changing and making sure we're using more natural ingredients."